aspirin has been researched along with Shock in 38 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
Shock: A pathological condition manifested by failure to perfuse or oxygenate vital organs.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Diaspirin cross-linked hemoglobin (DCLHb) is a vasoactive hemoglobin-based oxygen carrier or "blood substitute" that has been shown to improve base deficit in several experimental studies of hemorrhagic shock." | 7.70 | The effects of diaspirin cross-linked hemoglobin on hemodynamics, metabolic acidosis, and survival in burned rats. ( Hansbrough, JF; Soltero, RG, 1999) |
| "Diaspirin crosslinked hemoglobin (DCLHb; Baxter Healthcare Corp, Deerfield, IL) is hemoglobin-based oxygen carrier which, in our laboratory, improved hemodynamic parameters in a rat burn shock model." | 7.70 | Comparison of resuscitation with diaspirin crosslinked hemoglobin (DCLHb) vs fresh blood in a rat burn shock model. ( Hansbrough, JF; Soltero, RG, 1999) |
| " Association of bronchial asthma, nasal pathology and intolerance to aspirin is a unique syndrome." | 4.75 | Aspirin intolerance--a review. ( Abrishami, MA; Thomas, J, 1977) |
| "Diaspirin cross-linked hemoglobin (DCLHb) is a vasoactive hemoglobin-based oxygen carrier or "blood substitute" that has been shown to improve base deficit in several experimental studies of hemorrhagic shock." | 3.70 | The effects of diaspirin cross-linked hemoglobin on hemodynamics, metabolic acidosis, and survival in burned rats. ( Hansbrough, JF; Soltero, RG, 1999) |
| "Diaspirin crosslinked hemoglobin (DCLHb; Baxter Healthcare Corp, Deerfield, IL) is hemoglobin-based oxygen carrier which, in our laboratory, improved hemodynamic parameters in a rat burn shock model." | 3.70 | Comparison of resuscitation with diaspirin crosslinked hemoglobin (DCLHb) vs fresh blood in a rat burn shock model. ( Hansbrough, JF; Soltero, RG, 1999) |
| "We describe a case of recurrent Kawasaki disease (KD) in a non-Asian 6-year-old boy who had been diagnosed with typical KD without cardiac involvement at age 3 years." | 1.40 | Kawasaki shock syndrome complicating a recurrence of Kawasaki disease. ( Bœuf, B; Dauphin, C; Lang, M; Lusson, JR; Merlin, E; Tissandier, C, 2014) |
| "We report a 3-year-old girl with Kawasaki disease who presented with retropharyngeal edema and shock syndrome." | 1.40 | Unusual manifestations of Kawasaki disease with retropharyngeal edema and shock syndrome in a Taiwanese child. ( Chen, CK; Chu, SH; Fang, LC; Jim, WT; Kao, YH; Liu, LC; Peng, CC; Shyur, SD, 2014) |
| "The hypotension was found to be refractory to intravenous fluids, dopamine, and antihistamines, but was immediately reversed by intravenous epinephrine." | 1.26 | Shock syndrome associated with mastocytosis: pharmacologic reversal of the acute episode and therapeutic prevention of recurrent attacks. ( Oates, JA; Roberts, LJ; Turk, JW, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 20 (52.63) | 18.7374 |
| 1990's | 6 (15.79) | 18.2507 |
| 2000's | 2 (5.26) | 29.6817 |
| 2010's | 7 (18.42) | 24.3611 |
| 2020's | 3 (7.89) | 2.80 |
| Authors | Studies |
|---|---|
| Faraji, E | 1 |
| Sukumaran, S | 1 |
| Vijayan, V | 1 |
| Cattalini, M | 1 |
| Della Paolera, S | 1 |
| Zunica, F | 1 |
| Bracaglia, C | 1 |
| Giangreco, M | 1 |
| Verdoni, L | 1 |
| Meini, A | 1 |
| Sottile, R | 1 |
| Caorsi, R | 1 |
| Zuccotti, G | 1 |
| Fabi, M | 1 |
| Montin, D | 1 |
| Meneghel, A | 1 |
| Consolaro, A | 1 |
| Dellepiane, RM | 1 |
| Maggio, MC | 1 |
| La Torre, F | 1 |
| Marchesi, A | 1 |
| Simonini, G | 1 |
| Villani, A | 1 |
| Cimaz, R | 1 |
| Ravelli, A | 1 |
| Taddio, A | 1 |
| Gottlieb, M | 1 |
| Bridwell, R | 1 |
| Ravera, J | 1 |
| Long, B | 1 |
| Shavadia, J | 1 |
| Welsh, R | 1 |
| Gershlick, A | 1 |
| Zheng, Y | 1 |
| Huber, K | 1 |
| Halvorsen, S | 1 |
| Steg, PG | 1 |
| Van de Werf, F | 1 |
| Armstrong, PW | 1 |
| Ma, L | 1 |
| Zhang, YY | 1 |
| Yu, HG | 1 |
| Tissandier, C | 1 |
| Lang, M | 1 |
| Lusson, JR | 1 |
| Bœuf, B | 1 |
| Merlin, E | 1 |
| Dauphin, C | 1 |
| Camacho-Lovillo, MS | 1 |
| Melón, M | 1 |
| Moreno, MD | 1 |
| Ardanuy, AV | 1 |
| Neth, O | 1 |
| Singletary, EM | 1 |
| Zideman, DA | 1 |
| De Buck, ED | 1 |
| Chang, WT | 1 |
| Jensen, JL | 1 |
| Swain, JM | 1 |
| Woodin, JA | 1 |
| Blanchard, IE | 1 |
| Herrington, RA | 1 |
| Pellegrino, JL | 1 |
| Hood, NA | 1 |
| Lojero-Wheatley, LF | 1 |
| Markenson, DS | 1 |
| Yang, HJ | 1 |
| Liang, CM | 1 |
| Hsu, CN | 1 |
| Tai, WC | 1 |
| Yang, SC | 1 |
| Wu, CK | 1 |
| Shih, CW | 1 |
| Ku, MK | 1 |
| Yuan, LT | 1 |
| Wang, JW | 1 |
| Tseng, KL | 1 |
| Sun, WC | 1 |
| Hung, TH | 1 |
| Nguang, SH | 1 |
| Hsu, PI | 1 |
| Wu, DC | 1 |
| Chuah, SK | 1 |
| Fang, LC | 1 |
| Shyur, SD | 1 |
| Peng, CC | 1 |
| Jim, WT | 1 |
| Chu, SH | 1 |
| Kao, YH | 1 |
| Chen, CK | 1 |
| Liu, LC | 1 |
| Wong, F | 1 |
| KIMURA, Y | 1 |
| MURANAKA, M | 1 |
| BARNESS, LA | 2 |
| YOUNG, LN | 2 |
| Elad, S | 1 |
| Chackartchi, T | 1 |
| Shapira, L | 1 |
| Findler, M | 1 |
| Adams, HR | 1 |
| Kootte, AM | 1 |
| Haak, A | 1 |
| Roberts, LJ | 2 |
| Slichter, SJ | 1 |
| Turk, JW | 1 |
| Oates, JA | 1 |
| Warne, PJ | 1 |
| West, GB | 1 |
| Saeed, SA | 1 |
| Simjee, RU | 1 |
| Mahmood, F | 1 |
| Rahman, NN | 1 |
| Chappell, JE | 2 |
| McBride, WJ | 2 |
| Shackford, SR | 2 |
| Soltero, RG | 2 |
| Hansbrough, JF | 2 |
| Welter, HF | 1 |
| Lauterjung, KL | 1 |
| Isselhard, W | 1 |
| Abrishami, MA | 1 |
| Thomas, J | 1 |
| Benowitz, NL | 1 |
| Rosenberg, J | 1 |
| Becker, CE | 1 |
| Hormaechea, E | 1 |
| Carlson, RW | 1 |
| Rogove, H | 1 |
| Uphold, J | 1 |
| Henning, RJ | 1 |
| Weil, MH | 1 |
| Nelson, D | 1 |
| Hai, T | 1 |
| Srnak, A | 1 |
| Ebeling, A | 1 |
| Kunas, G | 1 |
| Catarello, J | 1 |
| Burhop, K | 1 |
| Bahr, T | 1 |
| Schaper, U | 1 |
| Becker, K | 1 |
| Lueddeckens, G | 1 |
| Förster, W | 1 |
| Scheuch, DW | 1 |
| Grupe, R | 1 |
| Seropian, E | 1 |
| Allen, JE | 1 |
| Valeri, CR | 1 |
| Iurenev, PN | 1 |
| Semenovich, NI | 1 |
| Nelson, NC | 1 |
| Nelson, JL | 1 |
| Weldon, WE | 1 |
| Vela, AR | 1 |
| Adebahr, G | 1 |
| Back, N | 1 |
| Jainchill, M | 1 |
| Wilkens, HJ | 1 |
| Ambrus, JL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| STREAM (Strategic Reperfusion Early After Myocardial Infarction). Comparison of the Efficacy and Safety of a Strategy of Early Fibrinolytic Treatment With Tenecteplase and Additional Antiplatelet and Antithrombin Therapy Followed by Catheterisation Within[NCT00623623] | Phase 3 | 1,899 participants (Actual) | Interventional | 2008-03-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
This is a key secondary endpoint. The number of observed patients with all cause death and non-fatal stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 50 |
| Primary PCI (Group B) | 43 |
This is a key secondary endpoint. The number of observed patients with all cause death and shock within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 59 |
| Primary PCI (Group B) | 73 |
This is a key secondary endpoint. The number of observed patients with all cause death and shock and CHF within 30 days was reported. (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 100 |
| Primary PCI (Group B) | 123 |
This is a key secondary endpoint. The number of observed patients with all cause death and shock and CHF and reinfarction and disabling stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 117 |
| Primary PCI (Group B) | 135 |
This is a key secondary endpoint. The number of observed patients with all cause death and shock and reinfarction within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 77 |
| Primary PCI (Group B) | 85 |
This is a key secondary endpoint. The number of observed patients with all cause mortality within 30 days was reported. (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 43 |
| Primary PCI (Group B) | 42 |
The number of observed patients with all-cause mortality, cardiogenic shock, congestive heart failure (CHF) and recurrent myocardial infarction within 30 days was reported for full analysis set (FAS). (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 116 |
| Primary PCI (Group B) | 135 |
This is a key secondary endpoint. The number of observed patients with cardiac mortality within 30 days was reported. (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 31 |
| Primary PCI (Group B) | 32 |
This is a key secondary endpoint. The number of observed patients with cardiogenic shock within 30 days was reported. (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 41 |
| Primary PCI (Group B) | 56 |
This is a key secondary endpoint. The number of observed patients with congestive heart failure (CHF) within 30 days was reported. (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 57 |
| Primary PCI (Group B) | 72 |
This is a key secondary endpoint. The number of observed patients with intracranial haemorrhage within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 9 |
| Primary PCI (Group B) | 2 |
This is a key secondary endpoint. The number of observed patients with ischaemic stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 6 |
| Primary PCI (Group B) | 3 |
This is a key secondary endpoint. The number of observed patients with major non-intracranial bleeds including blood transfusions within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 61 |
| Primary PCI (Group B) | 45 |
This is a key secondary endpoint. The number of observed patients with minor non-intracranial bleeds within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 206 |
| Primary PCI (Group B) | 191 |
This is a key secondary endpoint. The number of observed patients with recurrent myocardial infarction (reinfarction) within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 23 |
| Primary PCI (Group B) | 21 |
This is a key secondary endpoint. The number of observed patients with rehospitalisation for cardiac reasons within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 45 |
| Primary PCI (Group B) | 41 |
This is a key secondary endpoint. The number of observed patients with rehospitalisation for non-cardiac reasons within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 19 |
| Primary PCI (Group B) | 11 |
This is a key secondary endpoint. The number of observed patients with serious repeat target vessel revascularization within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 1 |
| Primary PCI (Group B) | 2 |
This is a key secondary endpoint. The number of observed patients with serious resuscitated ventricular fibrillation within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 32 |
| Primary PCI (Group B) | 38 |
This is a key secondary endpoint. The number of observed patients with serious resuscitated ventricular fibrillation in association with invasive procedures (occurring at any time during catheterisation or urgent/elective PCI) within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 10 |
| Primary PCI (Group B) | 29 |
This is a key secondary endpoint. The number of observed patients with total disabling stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 2 |
| Primary PCI (Group B) | 0 |
This is a key secondary endpoint. The number of observed patients with total fatal stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 7 |
| Primary PCI (Group B) | 4 |
This is a key secondary endpoint. The number of observed patients with total non-disabling stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 8 |
| Primary PCI (Group B) | 1 |
This is a key secondary endpoint. The number of observed patients with total non-intracranial bleeds within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 267 |
| Primary PCI (Group B) | 236 |
This is a key secondary endpoint. The number of observed patients with total stroke (all types) within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 15 |
| Primary PCI (Group B) | 5 |
7 reviews available for aspirin and Shock
| Article | Year |
|---|---|
Multisystem inflammatory syndrome in children with COVID-19.
Topics: Adolescent; Adrenal Cortex Hormones; Aspirin; Child; Child, Preschool; COVID-19; Emergency Service, | 2021 |
Part 9: First Aid: 2015 International Consensus on First Aid Science With Treatment Recommendations.
Topics: Airway Management; Aspirin; Asthma; Cardiopulmonary Resuscitation; Chest Pain; Emergencies; Emergenc | 2015 |
Liver and kidney diseases.
Topics: Acetaminophen; Anemia, Sickle Cell; Animals; Aspirin; Cholestasis; Cysts; Glomerulonephritis, IGA; G | 2002 |
Pharmacologic problems in shock research.
Topics: Adrenergic alpha-Antagonists; Aminoglycosides; Animals; Anti-Bacterial Agents; Anti-Inflammatory Age | 1983 |
Identification & management of defects in platelet hemostasis in massively transfused patients.
Topics: Animals; Aspirin; Bleeding Time; Blood Preservation; Blood Transfusion; Cardiopulmonary Bypass; Cell | 1982 |
Aspirin intolerance--a review.
Topics: Adolescent; Adult; Age Factors; Aged; Angioedema; Aspirin; Asthma; Blood Coagulation; Child; Child, | 1977 |
Prostaglandins in hematology.
Topics: Animals; Aspirin; Blood Coagulation; Blood Platelets; Blood Preservation; Blood Transfusion; Chromiu | 1974 |
31 other studies available for aspirin and Shock
| Article | Year |
|---|---|
A 3 Year Old With Fever and Rash: An Atypical Cause of Shock.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Child, Preschool; Diagnosis, Differential; Exanthe | 2020 |
Defining Kawasaki disease and pediatric inflammatory multisystem syndrome-temporally associated to SARS-CoV-2 infection during SARS-CoV-2 epidemic in Italy: results from a national, multicenter survey.
Topics: Age Distribution; Antirheumatic Agents; Aspirin; C-Reactive Protein; Child; Child, Preschool; Corona | 2021 |
Relationship Between Arterial Access and Outcomes in ST-Elevation Myocardial Infarction With a Pharmacoinvasive Versus Primary Percutaneous Coronary Intervention Strategy: Insights From the STrategic Reperfusion Early After Myocardial Infarction (STREAM)
Topics: Aged; Aspirin; Catheterization, Peripheral; Clopidogrel; Coronary Angiography; Enoxaparin; Female; F | 2016 |
Clinical Manifestations of Kawasaki Disease Shock Syndrome.
Topics: Adolescent; Albumins; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; Child; | 2018 |
Kawasaki shock syndrome complicating a recurrence of Kawasaki disease.
Topics: Aspirin; Child; Combined Modality Therapy; Diagnosis, Differential; Dose-Response Relationship, Drug | 2014 |
Kawasaki Disease Shock Syndrome (KDSS)--Presentation of 3 Children and Review of the Literature.
Topics: Adrenal Cortex Hormones; Aspirin; Child; Combined Modality Therapy; Female; Follow-Up Studies; Human | 2015 |
Risk factors influencing the outcome of peptic ulcer bleeding in chronic kidney disease after initial endoscopic hemostasis: A nationwide cohort study.
Topics: Adult; Age Factors; Aged; Aspirin; Female; Hemostasis, Endoscopic; Hospital Costs; Humans; Intubatio | 2016 |
Unusual manifestations of Kawasaki disease with retropharyngeal edema and shock syndrome in a Taiwanese child.
Topics: Aspirin; Cervix Uteri; Child, Preschool; Edema; Exanthema; Female; Fever; Humans; Immunoglobulins, I | 2014 |
[SHOCK-LIKE SYMPTOMS CAUSED BY DRUGS AND THEIR TREATMENT. (1) BASIC PRINCIPLES].
Topics: Adrenocorticotropic Hormone; Aminosalicylic Acid; Aminosalicylic Acids; Anaphylaxis; Anti-Bacterial | 1963 |
[SHOCK-LIKE SYMPTOMS CAUSED BY DRUGS AND THEIR TREATMENT. (2) CLINICAL ASPECTS].
Topics: Analgesics; Analgesics, Non-Narcotic; Antipyretics; Aspirin; Blood Chemical Analysis; Body Constitut | 1963 |
A SIMPLIFIED VIEW OF FLUID THERAPY.
Topics: Acidosis; Adrenal Insufficiency; Aspirin; Calcium; Child; Cystic Fibrosis; Dehydration; Diabetes Mel | 1964 |
A SIMPLIFIED VIEW OF FLUID THERAPY.
Topics: Acidosis; Adrenal Insufficiency; Anuria; Aspirin; Body Weight; Burns; Calcium; Child; Cystic Fibrosi | 1964 |
A critically severe gingival bleeding following non-surgical periodontal treatment in patients medicated with anti-platelet.
Topics: Aspirin; Clopidogrel; Drug Combinations; Female; Gingival Hemorrhage; Humans; Middle Aged; Periodont | 2008 |
The flush syndrome: an expression of systemic mastocytosis with increased prostaglandin D2 production.
Topics: Adult; Aspirin; Erythema; Humans; Hypotension; Male; Prostaglandin D2; Prostaglandins; Prostaglandin | 1983 |
Shock syndrome associated with mastocytosis: pharmacologic reversal of the acute episode and therapeutic prevention of recurrent attacks.
Topics: Aspirin; Chlorpheniramine; Cimetidine; Epinephrine; Humans; Hypotension; Infusions, Parenteral; Pros | 1982 |
Seasonal variation in drug action and animal responses in models of inflammation.
Topics: Anaphylaxis; Animals; Aspirin; Cell Movement; Dextrans; Drug Resistance; Glucose; Inflammation; Leuk | 1980 |
Dual inhibition of platelet-activating factor and arachidonic acid metabolism by ajmaline and effect on carrageenan-induced rat paw oedema.
Topics: Ajmaline; Animals; Arachidonic Acid; Aspirin; Blood Platelets; Carbon Radioisotopes; Carrageenan; Ed | 1993 |
Diaspirin cross-linked hemoglobin resuscitation improves cerebral perfusion after head injury and shock.
Topics: Animals; Aspirin; Blood Pressure; Brain Injuries; Cerebrovascular Circulation; Fluid Therapy; Hemody | 1996 |
Effect of hemodilution with diaspirin cross-linked hemoglobin on intracranial pressure, cerebral perfusion pressure, and fluid requirements after head injury and shock.
Topics: Animals; Aspirin; Blood Pressure; Body Water; Cardiac Output; Central Venous Pressure; Cerebral Cort | 1997 |
The effects of diaspirin cross-linked hemoglobin on hemodynamics, metabolic acidosis, and survival in burned rats.
Topics: Acidosis; Animals; Aspirin; Burns; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Therap | 1999 |
Comparison of resuscitation with diaspirin crosslinked hemoglobin (DCLHb) vs fresh blood in a rat burn shock model.
Topics: Animals; Aspirin; Blood Substitutes; Blood Transfusion; Burns; Hemodynamics; Hemoglobins; Male; Rats | 1999 |
Inhibition of platelet aggregation during hypovolemic hypotension by acetylsalicylic acid and artificial respiration.
Topics: Adenosine Diphosphate; Animals; Aspirin; Dogs; Histamine Release; Hypotension; Platelet Aggregation; | 1979 |
Cardiopulmonary catastrophes in drug-overdosed patients.
Topics: Adolescent; Adult; Amphetamines; Antidepressive Agents; Arrhythmias, Cardiac; Aspirin; Cardiovascula | 1979 |
Hypovolemia, pulmonary edema and protein changes in severe salicylate poisoning.
Topics: Adult; Aspirin; Blood Pressure; Blood Proteins; Blood Volume; Female; Hematocrit; Humans; Hypoprotei | 1979 |
Synthesis and properties of polymerized, diaspirin cross-linked hemoglobins.
Topics: Animals; Aspirin; Blood Substitutes; Chlorocebus aethiops; Cross-Linking Reagents; Drug Evaluation, | 1992 |
Influence of inhibitors of the eicosanoid metabolism, and of eicosanoids- and PAF-acether antagonists on mortality and some biochemical parameters of three shock models.
Topics: Anaphylaxis; Animals; Aspirin; Diterpenes; Fatty Acids, Unsaturated; Female; Ginkgolides; Imidazoles | 1989 |
[Clinical aspects of drug allergy].
Topics: Adolescent; Adult; Anaphylaxis; Aspirin; Asthma; Chloramphenicol; Drug Eruptions; Drug Hypersensitiv | 1967 |
[Desensitization therapy in myocardial infarct].
Topics: Adrenal Glands; Amines; Aminopyrine; Aspirin; Autoimmune Diseases; Desensitization, Immunologic; Dip | 1970 |
Mechanisms of change in thoracic duct lymph flow during hypotensive states.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Aspirin; Capillary Permeability; | 1970 |
[Therapy in decompression sickness and air embolism].
Topics: Abortion, Spontaneous; Adult; Air; Animals; Arteries; Aspirin; Blood Platelets; Capillaries; Child; | 1971 |
Effect of inhibitors of plasmin, kallikrein and kinin on mortality from scalding in mice.
Topics: Aminocaproates; Animals; Aprotinin; Aspirin; Burns; Enzyme Therapy; Male; Mice; Phenylbutazone; Sali | 1966 |